$GLYC News

Last published 1y ago

1y agoGLYCGlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related ProposalsBusiness Wire—GlycoMimetics Board of Directors approves 1-for-100 reverse stock split— GlycoMimetics, Inc. (NASDAQ:GLYC) ("GlycoMimetics") today announced that its stockholders have approved the proposed merger (the "Merger") with
1y agoGLYCCrescent Biopharma to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for
1y agoGLYCCrescent Biopharma Appoints David Lubner to Board of DirectorsGlobeNewswireIndustry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing
1y agoGLYCCrescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology TherapeuticsGlobeNewswireJonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D., Appointed Chief Medical Officer Additional Leadership Appointments: Rick Scalzo, MBA, as Chief Financial Officer, and Amy Reilly,
1y agoGLYCCrescent Biopharma to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireWALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to
2y agoGLYCGlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual MeetingBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American
2y agoGLYC PFIE RCM RVNCKuehn Law Encourages PFIE, GLYC, RVNC, and RCM Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
2y agoGLYCGlycoMimetics Enters Into Acquisition Agreement With Crescent BiopharmaBusiness WireFollowing closing, the combined company will advance Crescent's portfolio of precision-engineered biologics to improve outcomes for patients with solid tumors Crescent's lead program CR-001, a tetravalent PD-1 x VEGF
2y agoGLYCGlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary EndpointBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the Phase 2 analysis of the
2y agoGLYCGlycoMimetics Announces Strategic Review and Corporate Restructuring PlanBusiness WireAfter meeting with the U.S. Food and Drug Administration (FDA), it has been determined that the regulatory path forward for uproleselan in relapsed and refractory (R/R) Acute Myeloid Leukemia (AML) would require an
2y agoGLYCGlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Business WireCompany exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient
2y agoGLYCGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024Business WireGlycoMimetics, Inc. (NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key
2y agoGLYCGlycoMimetics, Inc. (GLYC) Corporate Update Call TranscriptEarnings Call Transcripts
2y agoGLYCGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)Business WireStudy of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect profiles of chemotherapy
2y agoGLYCGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024Business WireGlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone,
2y agoGLYCGlycoMimetics, Inc. (GLYC) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
2y agoGLYCGlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023Business WireTopline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) to be reported in Q2 2024 New Drug Application (NDA) for uproleselan to be submitted to the U.S.
2y agoGLYCGlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024Business WireGlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m. ET. To access
2y agoGLYCGlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care ConferenceBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Health Care Conference in Boston, MA on Monday, March 4,
2y agoGLYCGlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business WireGlycoMimetics, Inc. (the "Company") (NASDAQ:GLYC) today announced that the Compensation Committee of the Company's Board of Directors approved the grant on February 6, 2024 of a non-qualified stock option award to
2y agoGLYCGlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687Business WireFirst in human trial evaluating highly potent E-selectin antagonist, GMI-1687, met its primary and secondary endpoints with no dose-limiting toxicities or safety signals Single ascending dose study confirmed that
2y agoAPLM APLMW GLYCApollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaGlobeNewswireFOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat
2y agoGLYCGlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid LeukemiaBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced the 65th American Society of
3y agoGLYCGlycoMimetics to Participate in Upcoming Jefferies London Healthcare ConferenceBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16,
3y agoGLYCGlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023Business WireTopline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) on track to be reported by end of Q2 2024 NDA filing for uproleselan anticipated by end of 2024
3y agoANIX IMGN GLYC BPMCAnixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory BoardPR NewswireAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today...
3y agoGLYCGlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023Business WireGlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November 3, 2023, at 8:30 a.m. ET. To access the call by
3y agoGLYCGlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687Business WireGMI-1687, a highly potent E-selectin antagonist, is being developed as a potential point-of-care treatment for inflammatory diseases with initial focus on sickle cell disease (SCD) Single ascending dose study is
3y agoGLYCGlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment ConferenceBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York, NY on Wednesday, September 13,
3y agoGLYCGlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGlycoMimetics, Inc. (the "Company") (NASDAQ:GLYC) today announced that the Compensation Committee of the Company's Board of Directors approved the grant on August 14 , 2023 of a non-qualified stock option award to
3y agoGLYCGlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023Business WireTopline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) expected by end of Q2 2024 after addition of time-based analysis option U.S. Food and Drug
3y agoGLYCGlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023Business WireGlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, August 2, 2023, at 8:30 a.m. ET. To access the call by
3y agoGLYCGlycoMimetics Announces Its Addition to the Russell Microcap® IndexBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it is set to join the
3y agoGLYCGlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid LeukemiaBusiness WireFinal analysis to be conducted after the earlier of 295 survival events or the FDA-aligned cutoff date; topline results expected by the end of Q2 2024 Prolonged duration of blinded pooled survival in
3y agoGLYCGlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare ConferenceBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7, 2023 at
3y agoGLYCGlycoMimetics Reports Highlights and Financial Results for First Quarter 2023Business WirePivotal Phase 3 study of uproleselan combined with cytarabine-based chemotherapy in relapsed/refractory (R/R) acute myeloid leukemia (AML) continues to be projected to reach final survival event trigger within first
3y agoGLYCGlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023Business WireGlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3, 2023, at 8:30 a.m. ET. To access the call by
3y agoGLYCGlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022Business WireSignificant progress in strengthening leadership, raising capital, and preparing for final results of the uproleselan Phase 3 study in relapsed/refractory (R/R) acute myeloid leukemia (AML) Interim utility analysis
3y agoGLYCGlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023Business WireGlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on Wednesday, March 29, 2023, at 8:30 a.m. ET. To access
3y agoGLYCGlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care ConferenceBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 43rd Annual Health Care Conference in Boston, MA on Wednesday, March
3y agoGLYCGlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business WireGlycoMimetics, Inc. (the "Company") (NASDAQ:GLYC) today announced that the Compensation Committee of the Company's Board of Directors approved the grant on February 10, 2023 of a non-qualified stock option award to
3y agoGLYCGlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring CommitteeBusiness WireIndependent Data Monitoring Committee recommended pivotal Phase 3 study continue to the originally planned final overall survival events trigger and expressed no concerns about safety Interim utility analysis was
3y agoGLYCGlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business WireGlycoMimetics, Inc. (the "Company") (NASDAQ:GLYC) today announced that the Compensation Committee of the Company's Board of Directors approved the grant on January 31 , 2023 of a non-qualified stock option award to
3y agoGLYCGlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual MeetingBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced results from two
4y agoGLYCGlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022Business WireU.S. Food and Drug Administration (FDA) clears protocol amendment to conduct an interim utility analysis of pivotal Phase 3 study of uproleselan in relapsed/refractory acute myeloid leukemia (AML) Blinded pooled
4y agoGLYCGlycoMimetics to Participate in Two Upcoming Investor ConferencesBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC) today announced that management will participate in two upcoming investor conferences. The Stifel 2022 Healthcare Conference on November 15, 2022 – management will attend and host 1x1
4y agoGLYCGlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual MeetingBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that data from two
4y agoGLYCGlycoMimetics to Report Third Quarter Financial Results on November 9, 2022Business WireGlycoMimetics, Inc. (NASDAQ:GLYC), today announced that it will host a conference call and webcast to report third quarter financial results on Wednesday, November 9, 2022, at 8:30 a.m. ET. To access the call by phone,
4y agoGLYCGlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business WireGlycoMimetics, Inc. (the "Company") (NASDAQ:GLYC) today announced that the compensation committee of the Company's Board of Directors approved the grant on September 2, 2022 of a non-qualified stock option award to purchase an aggregate of 200,000 share
4y agoGLYCGlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment ConferenceBusiness WireGlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY on Wednesday, September 14, 2022 at 3:00 p.m. ET.